Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate

被引：26

作者：

Rebarber, Andrei ^{[1
]}

Ferrara, Lauren A.

Hanley, Maryellen L.

Istwan, Niki B.

Rhea, Debbie J.

Stanziano, Gary J.

Saltzman, Daniel H.

机构：

[1] Mt Sinai Sch Med, Dept Maternal Fetal Med, New York, NY USA

[2] Valley Hosp, Dept Internal Fetal Med, Paramus, NJ USA

[3] Matria Healthcare, Dept Clin Res, Marietta, GA USA

来源：

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 2007年 / 196卷 / 03期

关键词：

17-alpha-hydroxyprogesterone caproate; preterm birth prevention; recurrent spontaneous preterm delivery;

D O I：

10.1016/j.ajog.2007.01.002

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective: The purpose of this study was to identify the effect of early cessation of 17-alpha-hydroxyprogesterone caproate (17P) on the incidence of spontaneous recurrent preterm delivery (PTD). Study design: Retrospective analysis of data from women who were enrolled for outpatient 17P administration between January 2004 and May 2006 included women with previous PTD and current singleton pregnancy who were beginning weekly 17P injections (250 mg intramuscularly) at 16-20.9 weeks. The study group was comprised of patients who were electively terminating 17P at <32.0 weeks and who delivered >10 days from the last injection. The control group consisted of patients who received weekly 17P injections until PTD or 36.9 weeks of gestation. The primary study outcome was the rate of recurrent spontaneous PTD. Results: Study group patients were significantly more likely to have spontaneous recurrent PTD at <37 weeks of gestation (48.1% vs 33.3%; P = .011), at <35 weeks of gestation (30.9% vs 14.0%; P < .001), and at <32 weeks of gestation (16.0% vs 7.0%; P = .020). Conclusion: Early cessation of 17P treatment is associated with an increased risk for spontaneous recurrent PTD. © 2007 Mosby, Inc. All rights reserved.

引用

页码：224 / 225

页数：2

共 11 条

[1]

Meis P.J., Klevanoff M., Thom E., Et al., Prevention of recurrent preterm delivery by 17-alpha-hydroxyprogesterone caproate, N Engl J Med, 348, pp. 2379-2385, (2003)

[2]

Sanchez-Ramos L., Kaunitz A.M., Delke I., Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials, Obstet Gynecol, 105, pp. 273-279, (2005)

[3]

Mackenzie R., Walker M., Armson A., Hannah M.E., Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials, Am J Obstet Gynecol, 194, pp. 1234-1242, (2006)

[4]

Lockwood C.J., Predicting premature delivery: no easy task, N Engl J Med, 346, pp. 282-284, (2002)

[5]

Sexton D.J., O'Reilly M.W., Friel A.M., Morrison J.J., Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro, Reprod Biol Endocrinol, 2, (2004)

[6]

Papiernick-Berkhauer E., Double blind study of an agent to prevent preterm delivery among women with increased risk, Schering Edition, 4, pp. 65-68, (1970)

[7]

Goldstein P., Berrier J., Rosen S., Sacks H.S., Chalmers T.C., A meta-analysis of randomized control trials of progestational agents in pregnancy, BJOG, 96, pp. 265-274, (1989)

[8]

Escobar G.J., Clark R.H., Greene J.D., Short-term outcomes of infants born at 35 and 36 weeks gestation: we need to ask more questions, Semin Perinatol, 30, pp. 28-33, (2006)

[9]

Kramer M.S., Demissie K., Yang H Platt R.W., Suave R., Liston R., The contribution of mild and moderate preterm birth to infant mortality: fetal and infant health study group of the Canadian perinatal surveillance system, JAMA, 284, pp. 843-849, (2000)

[10]

Rubaltelli F.F., Dani C., Reali M.F., Et al., Acute neonatal respiratory distress in Italy a one-year prospective study, Acta Paediatr, 87, pp. 1261-1268, (1998)

← 1 2 →